Ioversol: Difference between revisions

Ioversol
Clinical data
Trade names	Optiray
AHFS/Drugs.com	Multum Consumer Information
Pregnancy; category	AU: B1; ;
ATC code	V08AB07 (WHO) ;
Legal status
Legal status	AU: Unscheduled; US: WARNING;
Pharmacokinetic data
Protein binding	Low
Metabolism	None
Elimination half-life	90 min
Excretion	Kidneys
Identifiers
	IUPAC name 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[2-hydroxy-N-(2-hydroxyethyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide;
CAS Number	87771-40-2 ;
PubChem CID	3741;
DrugBank	DB09134 ;
ChemSpider	3610 ;
UNII	N3RIB7X24K;
KEGG	D01555 ;
ChEMBL	ChEMBL1200614 ;
CompTox Dashboard (EPA)	DTXSID2045521 ;
ECHA InfoCard	100.118.911
Chemical and physical data
Formula	C18H24I3N3O9
Molar mass	807.115 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C(CO)N(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO;
	InChI InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33) ; Key:AMDBBAQNWSUWGN-UHFFFAOYSA-N ;
	(what is this?) (verify)

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

Inline

Latest revision as of 04:42, 20 March 2024

Ioversol (INN; trade name Optiray) is an organoiodine compound that is used as a contrast medium. It features both a high iodine content, as well as several hydrophilic groups. It is used in clinical diagnostics including arthrography, angiocardiography and urography.^[2]^[3]

References[edit]

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
^ "Optiray (ioversol) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 9 January 2021.
^ Chen Y, Huang X, Huang S, Matchett M (17 February 2011). "13. Fast-in-process method for the determination ioversol and related polar compounds by hydrophilic interactive chromatography". In Wang PG, He W (eds.). Hydrophilic Interaction Liquid Chromatography (HILIC) and Advanced Applications. CRC Press. p. 295-30. ISBN 978-1-4398-0753-8.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

[Medscape-2] "Optiray (ioversol) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 9 January 2021.

[Chen-3] Chen Y, Huang X, Huang S, Matchett M (17 February 2011). "13. Fast-in-process method for the determination ioversol and related polar compounds by hydrophilic interactive chromatography". In Wang PG, He W (eds.). Hydrophilic Interaction Liquid Chromatography (HILIC) and Advanced Applications. CRC Press. p. 295-30. ISBN 978-1-4398-0753-8.

[1]

[2]

[3]

@@ Line 1: / Line 1: @@
+{{Short description|Chemical compound}}
 {{Drugbox
+| Verifiedfields = changed
-| IUPAC_name        = 1-''N'',3-''N-bis''(2,3-dihydroxypropyl)-5-[2-hydroxy-''N''-(2-hydroxyethyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
+| Watchedfields = changed
-| image             = Ioversol.png
+| verifiedrevid = 407439500
-| CAS_number        =
+| image = Ioversol.png
-| ATC_prefix        = V08
+| alt =
-| ATC_suffix        = AB07
-| PubChem           = 3741
+<!--Clinical data-->
-| DrugBank          =
+| tradename = Optiray
-| chemical_formula  =
+| Drugs.com = {{drugs.com|MTM|ioversol}}
-|C=18|H=24|I=3|N=3|O=9
+| pregnancy_AU = B1
-| molecular_weight  = 807.11127
-| bioavailability   =
+| pregnancy_category =
-| protein_bound     =
-| metabolism        =
-| elimination_half-life =
-| excretion         =
-| pregnancy_AU      =  <!-- A / B1 / B2 / B3 / C / D / X -->
-| pregnancy_US      =  <!-- A / B            / C / D / X -->
-| pregnancy_category=
-| legal_AU =  <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
-| legal_CA =  <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
-| legal_UK =  <!-- GSL, P, POM, CD, or Class A, B, C -->
-| legal_US =  <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
-| legal_status      =
 | routes_of_administration =
+| ATC_prefix = V08
+| ATC_suffix = AB07
+| legal_AU = Unscheduled
+| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
+| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
+| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
+| legal_status =
+<!--Pharmacokinetic data-->
+| bioavailability =
+| protein_bound = Low
+| metabolism = None
+| elimination_half-life = 90 min
+| excretion = Kidneys
+<!--Identifiers-->
+| CAS_number_Ref = {{cascite|correct|??}}
+| CAS_number = 87771-40-2
+| PubChem = 3741
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
+| DrugBank = DB09134
+| UNII_Ref = {{fdacite|changed|FDA}}
+| UNII = N3RIB7X24K
+| KEGG_Ref = {{keggcite|correct|kegg}}
+| KEGG = D01555
+| ChEMBL_Ref = {{ebicite|changed|EBI}}
+| ChEMBL = 1200614
+| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
+| ChemSpiderID = 3610
+<!--Chemical data-->
+| IUPAC_name = 1-''N'',3-''N-bis''(2,3-dihydroxypropyl)-5-[2-hydroxy-''N''-(2-hydroxyethyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
+| C=18 | H=24 | I=3 | N=3 | O=9
+| smiles = C(CO)N(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO
+| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
+| StdInChI = 1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33)
+| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
+| StdInChIKey       = AMDBBAQNWSUWGN-UHFFFAOYSA-N
 }}
+'''Ioversol''' ([[International Nonproprietary Name|INN]]; trade name '''Optiray''') is an [[organoiodine compound]] that is used as a [[contrast medium]].  It features both a high iodine content, as well as several [[hydrophile|hydrophilic]] groups. It is used in clinical diagnostics including [[arthrography]], [[angiocardiography]] and [[urography]].<ref name="Medscape">{{cite web |title=Optiray (ioversol) dosing, indications, interactions, adverse effects, and more |url=https://reference.medscape.com/drug/optiray-ioversol-343759#0 |website=reference.medscape.com |access-date=9 January 2021}}</ref><ref name="Chen">{{cite book | vauthors = Chen Y, Huang X, Huang S, Matchett M | veditors = Wang PG, He W |title=Hydrophilic Interaction Liquid Chromatography (HILIC) and Advanced Applications |publisher=CRC Press |isbn=978-1-4398-0753-8 |page=295-30 |chapter-url= https://books.google.com/books?id=psoSZYLnGkcC&dq=ioversol&pg=PA295 |language=en |chapter=13. Fast-in-process method for the determination ioversol and related polar compounds by hydrophilic interactive chromatography| date = 17 February 2011 }}</ref>
-'''Ioversol''' is a molecule used as a [[contrast medium]].
+== References ==
+{{reflist}}
-{{pharmacology-stub}}
 {{Contrast media}}
+{{Portal bar | Medicine}}
+[[Category:Radiocontrast agents]]
+[[Category:Benzamides]]
+[[Category:Acetanilides]]
+[[Category:Iodobenzene derivatives]]
+{{pharmacology-stub}}